These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29462491)

  • 1. The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes.
    McMacken G; Cox D; Roos A; Müller J; Whittaker R; Lochmüller H
    Hum Mol Genet; 2018 May; 27(9):1556-1564. PubMed ID: 29462491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia.
    Webster RG; Vanhaesebrouck AE; Maxwell SE; Cossins JA; Liu W; Ueta R; Yamanashi Y; Beeson DMW
    Hum Mol Genet; 2020 Aug; 29(14):2325-2336. PubMed ID: 32543656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.
    McMacken GM; Spendiff S; Whittaker RG; O'Connor E; Howarth RM; Boczonadi V; Horvath R; Slater CR; Lochmüller H
    Hum Mol Genet; 2019 Jul; 28(14):2339-2351. PubMed ID: 31220253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
    Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
    Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders.
    Clausen L; Cossins J; Beeson D
    J Neuromuscul Dis; 2018; 5(2):231-240. PubMed ID: 29865088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dok-7 promotes slow muscle integrity as well as neuromuscular junction formation in a zebrafish model of congenital myasthenic syndromes.
    Müller JS; Jepson CD; Laval SH; Bushby K; Straub V; Lochmüller H
    Hum Mol Genet; 2010 May; 19(9):1726-40. PubMed ID: 20147321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromuscular junction involvement in inherited motor neuropathies: genetic heterogeneity and effect of oral salbutamol treatment.
    McMacken G; Whittaker RG; Wake R; Lochmuller H; Horvath R
    J Neurol; 2023 Jun; 270(6):3112-3119. PubMed ID: 36869887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation.
    Lorenzoni PJ; Scola RH; Kay CS; Filla L; Miranda AP; Pinheiro JM; Chaouch A; Lochmüller H; Werneck LC
    J Neurol Sci; 2013 Aug; 331(1-2):155-7. PubMed ID: 23790237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of β
    Rossi L; Mota BI; Valadão PAC; Magalhães-Gomes MPS; Oliveira BS; Guatimosim S; Navegantes LCC; Miranda AS; Prado MAM; Prado VF; Guatimosim C
    Neuropharmacology; 2024 Dec; 260():110116. PubMed ID: 39151654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital myasthenic syndromes and the formation of the neuromuscular junction.
    Beeson D; Webster R; Cossins J; Lashley D; Spearman H; Maxwell S; Slater CR; Newsom-Davis J; Palace J; Vincent A
    Ann N Y Acad Sci; 2008; 1132():99-103. PubMed ID: 18567858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular mechanisms underlying the formation of neuromuscular junction].
    Higuchi O; Yamanashi Y
    Brain Nerve; 2011 Jul; 63(7):649-55. PubMed ID: 21747134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
    Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
    Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.
    Sigoillot SM; Bourgeois F; Karmouch J; Molgó J; Dobbertin A; Chevalier C; Houlgatte R; Léger J; Legay C
    FASEB J; 2016 Jun; 30(6):2382-99. PubMed ID: 26993635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.
    Ohno K; Ohkawara B; Shen XM; Selcen D; Engel AG
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
    Tsao CY
    Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic defects and disorders at the neuromuscular junction].
    Ohno K
    Brain Nerve; 2011 Jul; 63(7):669-78. PubMed ID: 21747136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations.
    Burke G; Hiscock A; Klein A; Niks EH; Main M; Manzur AY; Ng J; de Vile C; Muntoni F; Beeson D; Robb S
    Neuromuscul Disord; 2013 Feb; 23(2):170-5. PubMed ID: 23219351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK.
    Gallenmüller C; Müller-Felber W; Dusl M; Stucka R; Guergueltcheva V; Blaschek A; von der Hagen M; Huebner A; Müller JS; Lochmüller H; Abicht A
    Neuromuscul Disord; 2014 Jan; 24(1):31-5. PubMed ID: 24183479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.
    Tezuka T; Inoue A; Hoshi T; Weatherbee SD; Burgess RW; Ueta R; Yamanashi Y
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16556-61. PubMed ID: 25368159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.
    Webster RG; Cossins J; Lashley D; Maxwell S; Liu WW; Wickens JR; Martinez-Martinez P; de Baets M; Beeson D
    Exp Neurol; 2013 Oct; 248():286-98. PubMed ID: 23797154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.